Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Harbour BioMed Out-Licenses SARS-COV-2 Antibody to AbbVie
Harbour BioMed (HBM), a US-China-Netherlands biopharma, has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie (NYSE: ABBV). The candidate is expected to prevent and treat the disease. HBM developed 47D11 together with
AbbVie will conduct the clinical development of the product, and if it is successful, it will manufacture and commercialize the product around the globe. The company will pay HBM and
HBM said the antibody targets a specific conserved region of the SARS-CoV-2 spike protein. It expects the candidate will treat cases of the existing pandemic, as well as future mutants of the virus.
The Phase I trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, pharmacokinetics and pharmacodynamics of single ascending doses of ABBV-47D11. Specifically, it is being examined in adults who are hospitalized with COVID-19.
"The rapid progress we have made to date is a credit to the outstanding research by our teams and university partners, the strength of HBM's fully human antibody discovery platform and AbbVie's world leading expertise in antibody and antiviral drug development," said Dr. Jingsong Wang, principal founder, executive director, chairman and CEO of HBM. "With the clinical program at AbbVie now underway, we are in a position to contribute a new therapeutic option to address this pandemic."
In August, HBM,
In the past, COVID-19 has been shown to break down NK cell immunity. Patients with a severe case of the disease often lack functional NK cells. The fully human, non-blocking antibody, 49F1, targets a specific region of the SARS-CoV-2 spike protein. It has also shown that it has strong binding affinity to both SARS-CoV-2 and a second coronavirus in vitro. HBM and AbbVie expect the candidate to eliminate the SARS-CoV-2 virus and virally infected cells by K-NK cells.
HBM currently has more than 30 programs in its pipeline, including an anti-CD73 monoclonal antibody and a bi-specific anti-BCMAxCD3 mAb. Its drug discovery operations are in
See our other articles on HBM and AbbVie.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China